Related Experiment Video
Updated: Jul 15, 2026
Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium
Published on: March 24, 2023
Autologous serum application in the treatment of Mooren's ulcer
N A Mavrakanas1, R Kiel, A A Dosso
1Eye Clinic, Geneva University Hospitals, Geneva, Switzerland.
Background:
Mooren's ulcer is a peripheral corneal ulceration of presumed autoimmune aetiology. Its clinical course and eventual prognosis is variable and usually these ulcers respond poorly to conventional therapy.
History And Signs:
A 67-year-old male was referred to our hospital for a painful, red and tearing left eye after receiving debris. Slit-lamp examination revealed a 3.2 x 2.1 mm peripheral corneal ulcer, a diffuse thinning of the lateral limbus (between 3 o'clock and 5 o'clock) and some endothelial precipitates. The conjunctiva was severely congested. In the anterior chamber, cells (++) and fibrin were found.
Therapy And Outcome:
We introduced an antibiotic, corticosteroid and cyclosporin therapy to treat the marginal corneal deficit caused by Mooren's ulcer. The patient did not respond to the initial treatment, but re-epithelialisation occurred and the corneal deficit improved after the introduction of autologous serum eye drops.
Conclusion:
Autologous serum seems to be an effective supplementary therapy in Mooren's ulcer.
Insights
Autologous serum eye drops show promise for treating Mooren's ulcer, a rare peripheral corneal condition. This supplementary therapy aided re-epithelialization when conventional treatments failed.
Area of Science:
- Ophthalmology
- Immunology
- Regenerative Medicine
Background:
- Mooren's ulcer is a peripheral corneal ulcer of autoimmune origin.
- This condition often presents with variable clinical courses and poor response to standard treatments.
- Understanding its autoimmune etiology is crucial for effective management.
Observation:
- A 67-year-old male presented with a painful left eye after ocular trauma.
- Examination revealed a peripheral corneal ulcer, limbal thinning, conjunctival congestion, and anterior chamber inflammation.
- Clinical signs indicated a significant inflammatory and ulcerative process.
Findings:
- Standard therapy including antibiotics, corticosteroids, and cyclosporine was ineffective.
- Introduction of autologous serum eye drops led to re-epithelialization.
- The corneal deficit showed improvement with the use of autologous serum.
Implications:
- Autologous serum may serve as an effective adjunctive therapy for Mooren's ulcer.
- This finding suggests a potential role for biological agents in managing refractory corneal ulcers.
- Further research into serum-based therapies could offer new hope for patients with Mooren's ulcer.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:31Diabetic Foot Ulcer